M. Villa

A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.

William H. Bisson, N. Cordani, W. Bisson, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma

Mario Mauri, S. Redaelli, C. Gambacorti-Passerini, 2021, Cancers.

New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)—Positive Cancer

G. Sharma, L. Mologni, D. Cortinovis, 2021, Cancers.

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients

Mario Mauri, C. Gambacorti-Passerini, R. Piazza, 2023, HemaSphere.

Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering

A. Graudenzi, R. Piazza, L. Mologni, 2023, Comput. Biol. Medicine.

Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients

Luca De Sano, M. Antoniotti, G. Caravagna, 2023, bioRxiv.

Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia

C. Voena, R. Chiarle, Mario Mauri, 2023, Journal of cellular and molecular medicine.

TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells

N. Cordani, M. Cerrito, Mario Mauri, 2023, International journal of molecular sciences.

New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients

N. Cordani, L. Mologni, D. Fontana, 2024, npj Precision Oncology.